Stock Rating Upgrade
Of late the Value Trend Rating for Sage Therapeutics Inc (NASDAQ: SAGE) improved from D to C reflecting improving fundamentals and high Appreciation Potential.
Recent Price Action
On 11/15/24, Sage Therapeutics Inc (NASDAQ: SAGE) stock suffered a large decline of -5.0%, closing at $5.10. Moreover, this decline was accompanied by unusually high trading volume at 171% of normal. Relative to the market the stock has been extremely weak over the last nine months and has declined -19.3% during the last week.
Current PriceTarget Research Rating
Sage Therapeutics has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Sage Therapeutics has a good Appreciation Score of 71 but a poor Power Rating of 20, leading to the Low Neutral Value Trend Rating.
Be the first to comment